The "cancer-targeting" antibodies that are currently in Phase I/II clinical trials include CD98
antibody, killer-cell immunoglobulin-like receptor (KIR) antibody, programed cell death protein 1 (PD1) antibody, Stage II-specific human thymocyte differentiation antigen (JL1) antibody, cytotoxic T-lymphocyte associated protein 4 (CTLA4) antibody, and CXCR4 antibody.[sup] More targets have yet to be discovered.
Several targets of MARCH1 have been identified: B7.2, CD98, CD95 (Fas), TfR, and MHC class II HLA-DR, -DM and -DO [6, 44, 46-50].
Overexpression of MARCH8 leads to the downregulation of several immunomodulatory receptors, including MHC I HLA 2.1, MHC II, CD95 (Fas), B7.2, TfR, CD166, CD44, CD88, and CD98, indicating that it plays a significant role in immune suppression [6, 15, 30, 31, 37, 46, 95, 96].
Horejsi et al., "The functional interactions between CD98, [beta]1-integrins, and CD147 in the induction of U937 homotypic aggregation," Blood, vol.
Cho, "Cell-permeable ceramides act as novel regulators of U937 cell-cell adhesion mediated by CD29, CD98, and CD147," Immunobiology, vol.
The mouse monoclonal antibody with specificity for anterior gradient protein 2 (AG-2, cat: sc-101211) and the goat polyclonal antibody with specificity for 4F2 cellsurface antigen heavy chain (CD98, cat: sc-31251) were purchased from Santa Cruz Biotechnology Inc.
To validate the iTRAQ-label and label-free quantitation results, we analyzed four downregulated cellular proteins by Western immunoblotting, including galectin-1 (LGALS1, or Gal1), galectin-3 (LGAL3, or Gal3), Anterior gradient protein 2 homolog (AG2), and CD98 (SLC3A2), an activator of dibasic and neutral amino acid transporter in both HAdV-B3- and HAdV-C5-infected cells.
This study was undertaken to examine the tissue distribution of a broad spectrum of monoclonal antibodies (mAbs) containing tetraspan antigens (CD9, CD63, CD151), endothelial cell antigens (CD31, CD36, CD105, CD106, CD146), integrins (CD49a-f, CD29, CD41, CD51, CD61), CD39, CD98, CD99, CD143 and, CD147 supplied from fifth and sixth international workshops and conferences on human leukocyte differentiation antigens in a comparative manner in human OA and normal synovium.
An intense reaction on the SLL and vascular endothelium was noted for CD98 in both normal and OA groups.
Joo et al., "Cynaropicrin, a sesquiterpene lactone, as a new strong regulator of CD29 and CD98
functions," Biochemical and Biophysical Research Communications, vol.
Currently, besides the above mentioned, CD147 binding partners include cyclophilins, caveolin-1, monocarboxylate transporters (MCT-1,3,4) , integrins , E-selectin , S100A9, CD98
, CD44, and CD147 itself  (Figure 1).
is expressed on astrocytes and activated T cells.